Lexeo Therapeutics, Common Stock Performance
| LXEO Stock | 4.05 0.39 8.78% |
The company secures a Beta (Market Risk) of 3.0, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lexeo Therapeutics, will likely underperform. At this point, Lexeo Therapeutics, has a negative expected return of -0.35%. Please make sure to verify Lexeo Therapeutics,'s potential upside and day median price , to decide if Lexeo Therapeutics, performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Lexeo Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 8.56 | Five Day Return 63.24 | Year To Date Return (33.43) | Ten Year Return (55.82) | All Time Return (55.82) |
1 | Acquisition by Omega Fund Vi, L.p. of 287213 shares of Lexeo Therapeutics, subject to Rule 16b-3 | 01/03/2025 |
2 | Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference | 01/07/2025 |
3 | Acquisition by Rasbach Kyle of 40875 shares of Lexeo Therapeutics, subject to Rule 16b-3 | 01/17/2025 |
4 | How Is Lexeo Therapeutics Advancing in the Biotechnology Market | 02/11/2025 |
5 | Disposition of 2101 shares by Jenny Robertson of Lexeo Therapeutics, at 4.413 subject to Rule 16b-3 | 02/19/2025 |
6 | Lexeo Therapeutics chief development officer sells shares worth 6,557 - Investing.com | 02/21/2025 |
7 | Disposition of tradable shares by Cholmondeley Paula H of Lexeo Therapeutics, subject to Rule 16b-3 | 03/07/2025 |
8 | Pharma Frenzy Volatility Ignites Biotech Sector | 03/25/2025 |
| Begin Period Cash Flow | 124.7 M |
Lexeo |
Lexeo Therapeutics, Relative Risk vs. Return Landscape
If you would invest 678.00 in Lexeo Therapeutics, Common on December 26, 2024 and sell it today you would lose (234.00) from holding Lexeo Therapeutics, Common or give up 34.51% of portfolio value over 90 days. Lexeo Therapeutics, Common is currently does not generate positive expected returns and assumes 9.0308% risk (volatility on return distribution) over the 90 days horizon. In different words, 80% of stocks are less volatile than Lexeo, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lexeo Therapeutics, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lexeo Therapeutics,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lexeo Therapeutics, Common, and traders can use it to determine the average amount a Lexeo Therapeutics,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.039
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LXEO |
Estimated Market Risk
| 9.03 actual daily | 80 80% of assets are less volatile |
Expected Return
| -0.35 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Lexeo Therapeutics, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lexeo Therapeutics, by adding Lexeo Therapeutics, to a well-diversified portfolio.
Lexeo Therapeutics, Fundamentals Growth
Lexeo Stock prices reflect investors' perceptions of the future prospects and financial health of Lexeo Therapeutics,, and Lexeo Therapeutics, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lexeo Stock performance.
| Return On Equity | -0.85 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 23.69 M | ||||
| Shares Outstanding | 33.08 M | ||||
| Price To Book | 1.16 X | ||||
| Gross Profit | (74.09 M) | ||||
| EBITDA | (105.14 M) | ||||
| Net Income | (98.33 M) | ||||
| Total Debt | 9.92 M | ||||
| Book Value Per Share | 3.53 X | ||||
| Cash Flow From Operations | (81.15 M) | ||||
| Earnings Per Share | (3.09) X | ||||
| Market Capitalization | 146.86 M | ||||
| Total Asset | 146.94 M | ||||
| Retained Earnings | (280.17 M) | ||||
| Working Capital | 103.28 M | ||||
About Lexeo Therapeutics, Performance
By examining Lexeo Therapeutics,'s fundamental ratios, stakeholders can obtain critical insights into Lexeo Therapeutics,'s financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Lexeo Therapeutics, is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.67) | (0.70) | |
| Return On Capital Employed | (0.64) | (0.67) | |
| Return On Assets | (0.67) | (0.70) | |
| Return On Equity | (0.84) | (0.80) |
Things to note about Lexeo Therapeutics, performance evaluation
Checking the ongoing alerts about Lexeo Therapeutics, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lexeo Therapeutics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lexeo Therapeutics, generated a negative expected return over the last 90 days | |
| Lexeo Therapeutics, has high historical volatility and very poor performance | |
| Net Loss for the year was (98.33 M) with loss before overhead, payroll, taxes, and interest of (74.09 M). | |
| Lexeo Therapeutics, generates negative cash flow from operations | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from marketbeat.com: Pharma Frenzy Volatility Ignites Biotech Sector |
- Analyzing Lexeo Therapeutics,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lexeo Therapeutics,'s stock is overvalued or undervalued compared to its peers.
- Examining Lexeo Therapeutics,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lexeo Therapeutics,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lexeo Therapeutics,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lexeo Therapeutics,'s stock. These opinions can provide insight into Lexeo Therapeutics,'s potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexeo Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexeo Therapeutics,. If investors know Lexeo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexeo Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lexeo Therapeutics, is measured differently than its book value, which is the value of Lexeo that is recorded on the company's balance sheet. Investors also form their own opinion of Lexeo Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Lexeo Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexeo Therapeutics,'s market value can be influenced by many factors that don't directly affect Lexeo Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexeo Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexeo Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexeo Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.